Your shopping cart is currently empty

RMC-4745 is a selective dual-site inhibitor of mTORC1, demonstrating a 35-fold selectivity over mTORC2. It inhibits the proliferation of MCF-7 cells and induces apoptosis by upregulating Caspase-3/7 activity. Notably, RMC-4745 does not trigger HER3 upregulation, which typically results from mTORC2 inhibition. This compound is useful for breast cancer research.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | RMC-4745 is a selective dual-site inhibitor of mTORC1, demonstrating a 35-fold selectivity over mTORC2. It inhibits the proliferation of MCF-7 cells and induces apoptosis by upregulating Caspase-3/7 activity. Notably, RMC-4745 does not trigger HER3 upregulation, which typically results from mTORC2 inhibition. This compound is useful for breast cancer research. |
| Cas No. | 2250059-80-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.